Business
Incorporation of Inaphaea BioLabs Limited
Incorporation of Inaphaea BioLabs Limited.
About this update from Valirx Plc
[{"type":"text","content":"\n \n \n 1 March 2023\n \n \n \n \n \n \n \n \n ValiRx PLC (\"ValiRx\" or the \"Company\")\n \n \n \n \n Incorporation of Inaphaea BioLabs Limited\n \n \n \n London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, today announces the incorporation of Inaphaea BioLabs Limited (\"Inaphaea\") as a new wholly owned subsidiary of the Company and the cornerstone of ValiRx's translational Contract Research Organisation (\"tCRO\").\n \n \n Inaphaea will be headquartered in the Company's laboratory in MediCity (Nottingham) and will offer a wide range of pre-clinical and drug discovery testing services to academic, biotech and pharmaceutical researchers; forming the foundational module of the Company's tCRO. A significant portion of the testing for ValiRx's evaluation pipeline, currently outsourced to external CROs, will be transferred into Inaphaea.\n \n \n Inaphaea will have the capability to conduct in vitro and ex vivo testing for all in-house pipeline and evaluation projects as well as to offer services to external users.\n \n \n Services will focus on the application of both standard and specialised cell-based technologies to generate deep biological understanding of drug candidates across preclinical phases of the drug development process. The laboratory is targeted to be fully operational within Q2 2023, with initial services focusing on cancer cell activity; allowing the study of drug candidates in a range of cell lines to elucidate activity, toxicity and mechanism of action of test molecules. ValiRx plans to add further techniques and novel data generation technologies to the testing portfolio, together with data analysis and application expertise, with the aim of providing deep biological understanding of drug candidates and help design effective clinical trials. Such new capabilities will be fully validated on in-house projects, before offering to external users. In due course, Inaphaea intends to build on the Company's expertise in specific tests that support the development of treatments in women's health.\n \n \n A highly experienced laboratory leadership team has been appointed, with Dr Dominic Lowen as Senior Scientist and Melissa Barr as Lead Scientist. The operational team will continue to grow as activity increases.\n \n \n In re...